10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks

10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks & will be assessed weekly

10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks

10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.

10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope

Psoriasis

Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks

Turmeric Extract

Turmeric Extract in Olive oil

Petrolatum

Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks

NB-UVB

calcipotriol/ Betamethasone

Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

Response to therapy is assessed via measurement of (PASI) every week for 12 w. The range of PASI score is from 0 (no disease) - 72 (sever disease). In PASI, the body is divided into four sections (head; arms; trunk; legs). Each of the sections is scored by itself, and then the four scores are combined into the final PASI. For each section, area of involved skin is given a grade from 0 to 6: 0= 0% of involved area, 1 = < 10% involved, 2=10-29% involved, 3 =30-49% involved area, 4 = 50-69% involved, 5 =70-89% involved, 6 = 90-100%involved. Within each section, the severity is estimated in three clinical parameters: erythema (redness), induration (thickness) and desquamation (scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum. The sum of three severity parameters is calculated for each section of body, multiplied by the area score for that section and multiplied by weight of respective section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs).

Histopathologic evaluation of hematoxylin and eosin stained slides from psoriatic lesions before and after treatment or placebo. The slides will be given a score based on the presence or absence of each of the following: Hyperkeratosis (0.5), One mitosis/3 rete ridges (0·5), Acanthosis (1),Dermis lymphocytic infiltrate; Mild (0·5) Moderate (1) Marked (2·0) Parakeratosis (1),Papillary congestion (0.5),Lack of granular layer (1), Munro abscesses (2), Thinning above the papillae (0.5), Length of rete ridges (0.5), Clubbing of rete ridges (0·5). The sum score of each patient's slide will be recorded at baseline & every 4 week

The NFϰB expression will be identified by the percentage of positive nuclear stained epidermal cells in slide at base line and every 4 weeks till the end of study which is 12 week

Response to therapy will be assessed using dermatoscope with software mediated image analysis.

Hagar Nofal

Assistant Lecturer, Principal Investigator

Zagazig University

Five groups will be included in the study Group 1: 10 Psoriatic patients receive turmeric extract based ointment . Group 2: 10 psoriatic patients will receive turmeric extract + olive oil based ointment.
Group 3: 10 psoriatic patients will receive petrolatum base as negative control.
Group 4: 10 psoriatic patients will receive NBUVB as positive control. Group 5: 10 psoriatic patients will receive established topical treatment serving as 2nd positive control.

The patients do not know whether they are receiving the drugs with active ingredients or negative control. The pathologist will be masked regarding the groups and the point of time before or after therapy.

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)

Non Small Cell Lung Cancer

β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days

β-elemene

EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

progression free survival ratio in 12 week

Yunpeng Liu

Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China

China Medical University, China

The First Affiliated Hospital of Dalian Medical University

The Second Affiliated Hospital of Dalian Medical University

Liaoning Tumor Hospital & Institute

Shengjing Hospital

General Hospital of Shenyang Military Region

2,000 mg turmeric per day - supplied by Banyan® Botanicals )
o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg.

• 2,000 mg Healthy Skin™ Tablets, contains:
Turmeric (Curcuma longa) - 50 mg/tablet
Hemidesmus Indicus root (Anantamul)
Indian Madder root
Neem leaf
Gotu Kola leaf
Indian TInospora stem
Amla fruit
Licorice root
Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets.

Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals
Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder
Dose: subjects in this group will take 2 tablets twice per day

Skin Inflammation

Turmeric

Turmeric-containing combination tablet

Placebo tablets

University of California, Davis Dermatology Clinical Trials Unit

Turmeric and Turmeric-containing Tablets and Sebum Production

Pilot Study on the Effects of Oral Turmeric and Turmeric-containing Tablets on Sebum Production

The investigators will use Sebutapes placed on the forehead to measure facial sebum production for 60 minutes at baseline and after 4 weeks. The tapes will collect the facial sebum produced during that time.

University of California, Davis

Tooth Brushing,massaging with whole turmeric powder

Chronic Periodontitis

Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Tooth Brushing with Dentifrice

:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.

Turmeric Massaging

on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects

SRP with turmeric massaging

Efficacy of Turmeric in Gingival Massaging and Adjunct to Scaling and Root Planing in Chronic Periodontitis Patient

To Evaluate the Efficacy of Whole Turmeric Powder in Gingival Massaging and as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis

curcuma rubrobracteata/syöpälääke

Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Turmeric and Turmeric-containing Tablets and Sebum Production

Efficacy of Turmeric in Gingival Massaging and Adjunct to Scaling and Root Planing in Chronic Periodontitis Patient

Täydellisin lääketieteellinen tietokanta tieteen tukemana